Beijing Aosaikang Pharmaceutical (002755.SZ) released a profit forecast, with an estimated net profit of 150 million to 195 million yuan for the fiscal year 2024, turning losses into profits compared to the previous year.
Auscon (002755.SZ) released its performance forecast for 2024, expecting the full-year attributable to the listed company's stock...
Beijing Aosaikang Pharmaceutical (002755.SZ) released its 2024 performance forecast, expecting a net profit attributable to shareholders of the listed company of 150 million to 195 million yuan for the full year, turning losses into profits year-on-year. During the reporting period, the company's sales of anti-infection and chronic disease products grew rapidly, with its operating revenue increasing year-on-year and profitability further improving.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
